Table 1.
Effect of long-term treatment with CDDO-Me on the incidence and distribution of pathologic lesions in the prostatic lobes.
| Prostate lobe | Pre-neoplastic lesions | Adenocarcinoma | ||||
|---|---|---|---|---|---|---|
| Normal | LG-PIN | HG-PIN | WD | MD | PD | |
|
| ||||||
| DLP | ||||||
| Control | 0/14 (0%) | 0/14 (0%) | 4/14 (29%) | 9/14 (64%) | 1/14 (7%) | 0/14 (0%) |
| CDDO-Me | 0/14 (0%) | 3/14 (22%) | 7/14 (50%) | 4/14 (29%) | 0/14 (0%) | 0/14 (0%) |
| VP | ||||||
| Control | 0/14 (0%) | 0/14 (0%) | 5/14 (36%) | 8/14 (57%) | 1/14 (7%) | 0/14 (0%) |
| CDDO-Me | 1/14 (7%) | 5/14 (36%) | 6/14 (43%) | 1/14 (7%) | 0/14 (0%) | 1/14 (7%) |
DLP: dorsolateral prostate;VP: ventral prostate;LG-PINL: low-grade PIN;HG-PIN: high-grade PIN; WD: well differentiated;MD: moderately differentiated;PD: poorly differentiated